Pharmacoinformatics and Preclinical Studies of NSC765690 and NSC765599, Potential STAT3/CDK2/4/6 Inhibitors with Antitumor Activities against NCI60 Human Tumor Cell Lines
Signal transducer and activator of transcription 3 (STAT3) is a transcriptional regulator of a number of biological processes including cell differentiation, proliferation, survival, and angiogenesis, while cyclin-dependent kinases (CDKs) are a critical regulator of cell cycle progression. These pro...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-01-01
|
| Series: | Biomedicines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9059/9/1/92 |
| _version_ | 1797409862904184832 |
|---|---|
| author | Bashir Lawal Yen-Lin Liu Ntlotlang Mokgautsi Harshita Khedkar Maryam Rachmawati Sumitra Alexander T. H. Wu Hsu-Shan Huang |
| author_facet | Bashir Lawal Yen-Lin Liu Ntlotlang Mokgautsi Harshita Khedkar Maryam Rachmawati Sumitra Alexander T. H. Wu Hsu-Shan Huang |
| author_sort | Bashir Lawal |
| collection | DOAJ |
| description | Signal transducer and activator of transcription 3 (STAT3) is a transcriptional regulator of a number of biological processes including cell differentiation, proliferation, survival, and angiogenesis, while cyclin-dependent kinases (CDKs) are a critical regulator of cell cycle progression. These proteins appear to play central roles in angiogenesis and cell survival and are widely implicated in tumor progression. In this study, we used the well-characterized US National Cancer Institute 60 (NCI60) human tumor cell lines to screen the in vitro anti-cancer activities of our novel small molecule derivatives (NSC765690 and NSC765599) of salicylanilide. Furthermore, we used the DTP-COMPARE algorithm and in silico drug target prediction to identify the potential molecular targets, and finally, we used molecular docking to assess the interaction between the compounds and prominent potential targets. We found that NSC765690 and NSC765599 exhibited an anti-proliferative effect against the 60 panels of NCI human cancer cell lines, and dose-dependent cytotoxic preference for NSCLC, melanoma, renal, and breast cancer cell lines. Protein–ligand interactions studies revealed that NSC765690 and NSC765599 were favored ligands for STAT3/CDK2/4/6. Moreover, cyclization of the salicylanilide core scaffold of NSC765690 mediated its higher anti-cancer activities and had greater potential to interact with STAT3/CDK2/4/6 than did NSC765599 with an open-ring structure. NSC765690 and NSC765599 met the required safety and criteria of a good drug candidate, and are thus worthy of further in-vitro and in-vivo investigations in tumor-bearing mice to assess their full therapeutic efficacy. |
| first_indexed | 2024-03-09T04:21:43Z |
| format | Article |
| id | doaj.art-2d77ecc0be4a4debbbd7424030dfec5e |
| institution | Directory Open Access Journal |
| issn | 2227-9059 |
| language | English |
| last_indexed | 2024-03-09T04:21:43Z |
| publishDate | 2021-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomedicines |
| spelling | doaj.art-2d77ecc0be4a4debbbd7424030dfec5e2023-12-03T13:46:05ZengMDPI AGBiomedicines2227-90592021-01-01919210.3390/biomedicines9010092Pharmacoinformatics and Preclinical Studies of NSC765690 and NSC765599, Potential STAT3/CDK2/4/6 Inhibitors with Antitumor Activities against NCI60 Human Tumor Cell LinesBashir Lawal0Yen-Lin Liu1Ntlotlang Mokgautsi2Harshita Khedkar3Maryam Rachmawati Sumitra4Alexander T. H. Wu5Hsu-Shan Huang6PhD Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University and Academia Sinica, Taipei 11031, TaiwanDepartment of Pediatrics, Taipei Medical University Hospital, Taipei 11031, TaiwanPhD Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University and Academia Sinica, Taipei 11031, TaiwanPhD Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University and Academia Sinica, Taipei 11031, TaiwanPhD Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University and Academia Sinica, Taipei 11031, TaiwanTMU Research Center of Cancer Translational Medicine, Taipei Medical University, Taipei 11031, TaiwanPhD Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University and Academia Sinica, Taipei 11031, TaiwanSignal transducer and activator of transcription 3 (STAT3) is a transcriptional regulator of a number of biological processes including cell differentiation, proliferation, survival, and angiogenesis, while cyclin-dependent kinases (CDKs) are a critical regulator of cell cycle progression. These proteins appear to play central roles in angiogenesis and cell survival and are widely implicated in tumor progression. In this study, we used the well-characterized US National Cancer Institute 60 (NCI60) human tumor cell lines to screen the in vitro anti-cancer activities of our novel small molecule derivatives (NSC765690 and NSC765599) of salicylanilide. Furthermore, we used the DTP-COMPARE algorithm and in silico drug target prediction to identify the potential molecular targets, and finally, we used molecular docking to assess the interaction between the compounds and prominent potential targets. We found that NSC765690 and NSC765599 exhibited an anti-proliferative effect against the 60 panels of NCI human cancer cell lines, and dose-dependent cytotoxic preference for NSCLC, melanoma, renal, and breast cancer cell lines. Protein–ligand interactions studies revealed that NSC765690 and NSC765599 were favored ligands for STAT3/CDK2/4/6. Moreover, cyclization of the salicylanilide core scaffold of NSC765690 mediated its higher anti-cancer activities and had greater potential to interact with STAT3/CDK2/4/6 than did NSC765599 with an open-ring structure. NSC765690 and NSC765599 met the required safety and criteria of a good drug candidate, and are thus worthy of further in-vitro and in-vivo investigations in tumor-bearing mice to assess their full therapeutic efficacy.https://www.mdpi.com/2227-9059/9/1/92protein-ligand interactionmolecular docking simulationtarget identificationsmall-molecule derivatives of salicylanilidedrug discoverydrug development |
| spellingShingle | Bashir Lawal Yen-Lin Liu Ntlotlang Mokgautsi Harshita Khedkar Maryam Rachmawati Sumitra Alexander T. H. Wu Hsu-Shan Huang Pharmacoinformatics and Preclinical Studies of NSC765690 and NSC765599, Potential STAT3/CDK2/4/6 Inhibitors with Antitumor Activities against NCI60 Human Tumor Cell Lines Biomedicines protein-ligand interaction molecular docking simulation target identification small-molecule derivatives of salicylanilide drug discovery drug development |
| title | Pharmacoinformatics and Preclinical Studies of NSC765690 and NSC765599, Potential STAT3/CDK2/4/6 Inhibitors with Antitumor Activities against NCI60 Human Tumor Cell Lines |
| title_full | Pharmacoinformatics and Preclinical Studies of NSC765690 and NSC765599, Potential STAT3/CDK2/4/6 Inhibitors with Antitumor Activities against NCI60 Human Tumor Cell Lines |
| title_fullStr | Pharmacoinformatics and Preclinical Studies of NSC765690 and NSC765599, Potential STAT3/CDK2/4/6 Inhibitors with Antitumor Activities against NCI60 Human Tumor Cell Lines |
| title_full_unstemmed | Pharmacoinformatics and Preclinical Studies of NSC765690 and NSC765599, Potential STAT3/CDK2/4/6 Inhibitors with Antitumor Activities against NCI60 Human Tumor Cell Lines |
| title_short | Pharmacoinformatics and Preclinical Studies of NSC765690 and NSC765599, Potential STAT3/CDK2/4/6 Inhibitors with Antitumor Activities against NCI60 Human Tumor Cell Lines |
| title_sort | pharmacoinformatics and preclinical studies of nsc765690 and nsc765599 potential stat3 cdk2 4 6 inhibitors with antitumor activities against nci60 human tumor cell lines |
| topic | protein-ligand interaction molecular docking simulation target identification small-molecule derivatives of salicylanilide drug discovery drug development |
| url | https://www.mdpi.com/2227-9059/9/1/92 |
| work_keys_str_mv | AT bashirlawal pharmacoinformaticsandpreclinicalstudiesofnsc765690andnsc765599potentialstat3cdk246inhibitorswithantitumoractivitiesagainstnci60humantumorcelllines AT yenlinliu pharmacoinformaticsandpreclinicalstudiesofnsc765690andnsc765599potentialstat3cdk246inhibitorswithantitumoractivitiesagainstnci60humantumorcelllines AT ntlotlangmokgautsi pharmacoinformaticsandpreclinicalstudiesofnsc765690andnsc765599potentialstat3cdk246inhibitorswithantitumoractivitiesagainstnci60humantumorcelllines AT harshitakhedkar pharmacoinformaticsandpreclinicalstudiesofnsc765690andnsc765599potentialstat3cdk246inhibitorswithantitumoractivitiesagainstnci60humantumorcelllines AT maryamrachmawatisumitra pharmacoinformaticsandpreclinicalstudiesofnsc765690andnsc765599potentialstat3cdk246inhibitorswithantitumoractivitiesagainstnci60humantumorcelllines AT alexanderthwu pharmacoinformaticsandpreclinicalstudiesofnsc765690andnsc765599potentialstat3cdk246inhibitorswithantitumoractivitiesagainstnci60humantumorcelllines AT hsushanhuang pharmacoinformaticsandpreclinicalstudiesofnsc765690andnsc765599potentialstat3cdk246inhibitorswithantitumoractivitiesagainstnci60humantumorcelllines |